Changes in vertebral strength-density and energy absorption-density relationships following bisphosphonate treatment in beagle dogs

Osteoporosis International

Volumn 19, Issue 1, 2008, Pages 95-99

  Allen, M R ^a   Burr, D B ^a,b  

^a INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Indiana University Purdue University Indianapolis   (United States)

Author keywords

Alendronate; Animal models; Mechanics; Risedronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; RISEDRONIC ACID;

ANALYSIS OF COVARIANCE; ANIMAL EXPERIMENT; ARTICLE; BONE DENSITY; BONE STRENGTH; CONTROLLED STUDY; DOG; DRUG MECHANISM; ENERGY ABSORPTION; FEMALE; NONHUMAN; PRIORITY JOURNAL; VERTEBRA BODY;

ALENDRONATE; ANIMALS; BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; COMPRESSIVE STRENGTH; DIPHOSPHONATES; DOGS; ETIDRONIC ACID; FEMALE; LUMBAR VERTEBRAE; MODELS, ANIMAL;

EID: 36649036563     PISSN: 0937941X     EISSN: 14332965     Source Type: Journal    
DOI: 10.1007/s00198-007-0451-8     Document Type: Article

References (22)

1. Delmas PD, Li Z, Cooper C (2004) Relationship between changes in bone mineral density and fracture risk reduction with antiresorptive drugs: some issues with meta-analyses. J Bone Miner Res 19:330-337
2. Delmas PD, Seeman E (2004) Changes in bone mineral density explain little of the reduction in vertebral or nonvertebral fracture risk with anti-resorptive therapy. Bone 34:599-604
3. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group. Lancet 348:1535-1541
4. Ettinger B, Black DM, Mitlak BH, Knickerbocker RK, Nickelsen T, Genant HK, Christiansen C, Delmas PD, Zanchetta JR, Stakkestad J, Gluer CC, Krueger K, Cohen FJ, Eckert S, Ensrud KE, Avioli LV, Lips P, Cummings SR (1999) Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators. JAMA 282:637-645
5. Harris ST, Watts NB, Genant HK, McKeever CD, Hangartner T, Keller M, Chesnut CH 3rd, Brown J, Eriksen EF, Hoseyni MS, Axelrod DW, Miller PD (1999) Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 282:1344-1352
6. Hernandez C, Keaveny T (2006) A biomechanical perspective on bone quality. Bone 39:1173-1181
7. Turner CH, Burr DB (1993) Basic biomechanical measurements of bone: a tutorial. Bone 14:595-608
8. Allen MR, Iwata K, Phipps R, Burr DB (2006) Alterations in canine vertebral bone turnover, microdamage accumulation, and biomechanical properties following 1-year treatment with clinical treatment doses of risedronate or alendronate. Bone 39:872-879
9. Allen MR, Iwata K, Sato M, Burr DB (2006) Raloxifene enhances vertebral mechanical properties independent of bone density. Bone 39:1130-1135
10. Mashiba T, Turner CH, Hirano T, Forwood MR, Johnston CC, Burr DB (2001) Effects of suppressed bone turnover by bisphosphonates on microdamage accumulation and biomechanical properties in clinically relevant skeletal sites in beagles. Bone 28:524-531
11. Currey JD (2001) Bone strength: what are we trying to measure? Calcif Tissue Int 68:205-210
12. Currey JD (2004) Tensile yield in compact bone is determined by strain, post-yield behaviour by mineral content. J Biomech 37:549-556
13. Currey JD, Brear K, Zioupos P (1996) The effects of ageing and changes in mineral content in degrading the toughness of human femora. J Biomech 29:257-260
14. Burr D (2002) The contribution of the organic matrix to bone's material properties. Bone 31:8-11
15. Boivin GY, Chavassieux PM, Santora AC, Yates J, Meunier PJ (2000) Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women. Bone 27:687-694
16. Roschger P, Rinnerthaler S, Yates J, Rodan GA, Fratzl P, Klaushofer K (2001) Alendronate increases degree and uniformity of mineralization in cancellous bone and decreases the porosity in cortical bone of osteoporotic women. Bone 29:185-191
17. Zoehrer R, Roschger P, Paschalis EP, Hofstaetter JG, Durchschlag E, Fratzl P, Phipps R, Klaushofer K (2006) Effects of 3- and 5-year treatment with risedronate on bone mineralization density distribution in triple biopsies of the iliac crest in postmenopausal women. J Bone Miner Res 21:1106-1112
18. Gineyts E, Allen MR, Burr DB, Delmas PD (2006) Effects of Antiresorptive Therapy on the Bone Tissue Concentration of Enzymatic Mature Collagen Crosslinks and Pentosidine. J Bone Miner Res 21(Supp 1):M344
19. Vashishth D, Wu P, Gibson G (2004) Age-related loss in bone toughness is explained by non-enzymatic glycation of collagen. Trans Orthop Res Soc 29
20. Hernandez CJ, Gupta A, Keaveny TM (2006) A biomechanical analysis of the effects of resorption cavities on cancellous bone strength. J Bone Miner Res 21:1248-1255
21. Wachter NJ, Augat P, Mentzel M, Sarkar MR, Krischak GD, Kinzl L, Claes LE (2001) Predictive value of bone mineral density and morphology determined by peripheral quantitative computed tomography for cancellous bone strength of the proximal femur. Bone 28:133-139
22. Rosen CJ, Hochberg MC, Bonnick SL, McClung M, Miller P, Broy S, Kagan R, Chen E, Petruschke RA, Thompson DE, de Papp AE (2005) Treatment with once-weekly alendronate 70 mg compared with once-weekly risedronate 35 mg in women with postmenopausal osteoporosis: a randomized double-blind study. J Bone Miner Res 20:141-151